Strides Shasun launches popular store brand H2 blocker
Strides Shasun on Monday introduced its Ranitidine Tablets, USP, 150 mg, the generic equivalent to the nonprescription Zantac digestive brand, to the U.S. marketplace. Strides Shasun already has a prescription-only rantidine product on the market in both 150 mg and 300 mg strengths.
Citing IRI data, Bangalore, India-based Strides Shasun reported Sanofi's Zantac generated some $200 million in sales.
This marks the first product approval to stem from the 50/50 joint venture with Vivimed Labs. The product will be backward integrated and will be manufactured at the JV's oral dosage facility in Chennai, India. Strides will have exclusive marketing rights for the product in the U.S. and will begin launching the product into the market immediately.
Ranitidine belongs to a class of drugs known as H2 histamine blockers. It is used to treat peptic ulcers of the stomach and intestines and gastroesophageal reflux and heartburn related to indigestion.
Strides Shasun has 82 cumulative ANDA filings before the Food and Drug Administration, of which 50 have been approved and 32 are pending approval, the company reported.
Citing IRI data, Bangalore, India-based Strides Shasun reported Sanofi's Zantac generated some $200 million in sales.
This marks the first product approval to stem from the 50/50 joint venture with Vivimed Labs. The product will be backward integrated and will be manufactured at the JV's oral dosage facility in Chennai, India. Strides will have exclusive marketing rights for the product in the U.S. and will begin launching the product into the market immediately.
Ranitidine belongs to a class of drugs known as H2 histamine blockers. It is used to treat peptic ulcers of the stomach and intestines and gastroesophageal reflux and heartburn related to indigestion.
Strides Shasun has 82 cumulative ANDA filings before the Food and Drug Administration, of which 50 have been approved and 32 are pending approval, the company reported.